Torisel temsirolimus

Drug Class

mTOR inhibitor

Mechanism

Binds to intracellular FKBP-12, forming a complex that inhibits mTOR kinase activity and arrests cell cycle progression in the G1 phase while blocking angiogenesis.

Approved Indication

Advanced renal cell carcinoma, per its FDA approval.

What This Means For Patients

Torisel is an intravenous targeted therapy for patients with advanced kidney cancer (renal cell carcinoma). It acts by inhibiting the mTOR pathway, which controls tumor growth and blood vessel formation, and can be accessed at Hainan Boao Lecheng.

Regulatory Approvals

• FDA — approved (2007) — label

Pivotal Clinical Evidence

• Global ARCC — Hudes et al., N Engl J Med 2007 (NCT00065910) — DOI

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-temsirolimus-advanced-renal-cell-carcinoma
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022088s000lbl.pdf